Biggest News Aggregation in the World
📰 Rom News

Page 363 - Rom News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Rom. Real-time updates on events, politics, business and more.

Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)

- Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable
United States Andrew Robbins Christi Waarich Andrew Wagner American Society Of Clinical Oncology Harvard Medical School

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Elicio Therapeutics Announces Positive Interim Data from the Phase 1 Study of an Investigational Therapeutic Cancer Immunotherapy, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at the ASCO Annual Meeting

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearanceRobust
United States Massachusetts Institute Of Technology Mccormick Place Gloria Gasaatura Eileenm Oreilly Darrell Irvine

NewAmsterdam Pharma Company B.V.: NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023

- Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p - 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of - New Data Demonstrate
United States Noord Holland Hannah Deresiewicz Christiem Ballantyne Matthew Philippe Company Phase

Replimune Group Inc: Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no progression
Chris Brinzey Arleen Goldenberg Robert Coffin Exchange Commission Research Development Bristol Myers Squibb

Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting

Puma Biotechnology, Inc. , a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone in metastatic... | June 4, 2023
United States Baylor University Saraa Byron Sara Byron Joycea Oshaughnessy Alanh Auerbach

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science